Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2024 | Acute Coronary Syndrome | Systematic Review

Systemic immune-inflammation index as a novel predictor of major adverse cardiovascular events in patients undergoing percutaneous coronary intervention: a meta-analysis of cohort studies

Authors: Chunyu Zhang, Minghao Li, Lin Liu, Li Deng, Xie Yulei, Yi Zhong, Bin Liao, Lu Yu, Jian Feng

Published in: BMC Cardiovascular Disorders | Issue 1/2024

Abstract

Background

The Systemic Immune-Inflammation Index (SII), a novel marker of inflammation based on neutrophil, platelet, and lymphocyte counts, has demonstrated potential prognostic value in patients undergoing percutaneous coronary intervention (PCI). Our aim was to assess the correlation between the SII and major adverse cardiovascular events following percutaneous coronary intervention.

Methods

We searched PubMed, Web of Science, Embase, and The Cochrane Library from inception to November 20, 2023, for cohort studies investigating the association between SII and the occurrence of MACEs after PCI. Statistical analysis was performed using Revman 5.3, with risk ratios (RRs) and 95% confidence intervals (CIs) as relevant parameters.

Results

In our analysis, we incorporated a total of 8 studies involving 11,117 participants. Our findings revealed that a high SII is independently linked to a increased risk of MACEs in PCI patients (RR: 2.08,95%CI: 1.87–2.32, I² = 42%, p < 0.00001). Additionally, we demonstrated the prognostic value of SII in all-cause mortality, heart failure, and non-fatal myocardial infarction.

Conclusions

Elevated SII may serve as a potential predictor for subsequent occurrence of MACEs in patients undergoing PCI.

Trial registration

Our protocol was registered in PROSPERO (registration number: CRD42024499676).

Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492.

Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362(23):2155–65.PubMedCrossRef

Zheng X, Curtis JP, Hu S, Wang Y, Yang Y, Masoudi FA, et al. Coronary catheterization and percutaneous coronary intervention in China: 10-year results from the China PEACE-retrospective CathPCI Study. JAMA Intern Med. 2016;176(4):512–21.PubMedPubMedCentralCrossRef

Ren H, Zhao L, Liu Y, Tan Z, Luo G, Deng X. The high-sensitivity C-reactive protein to prealbumin ratio predicts adverse cardiovascular events after ST-Elevation myocardial infarction. Heart Surg Forum. 2021;24(1):E153–7.PubMedCrossRef

Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, et al. P2Y(12) inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2023;82(2):89–105.PubMedCrossRef

Henry TD, Tomey MI, Tamis-Holland JE, Thiele H, Rao SV, Menon V, et al. Invasive management of acute myocardial infarction complicated by cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2021;143(15):e815–29.PubMedCrossRef

Docherty KF, Ferreira JP, Sharma A, Girerd N, Gregson J, Duarte K, et al. Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. Eur J Heart Fail. 2020;22(5):848–55.PubMedCrossRef

Arai R, Okumura Y, Murata N, Fukamachi D, Honda S, Nishihira K, et al. Prevalence and impact of polyvascular disease in patients with acute myocardial infarction in the contemporary era of percutaneous coronary intervention- insights from the Japan Acute Myocardial Infarction Registry (JAMIR). Circ J. 2023. Online ahead of print.

Shimono H, Tokushige A, Kanda D, Ohno A, Hayashi M, Fukuyado M, et al. Association of preoperative clinical frailty and clinical outcomes in elderly patients with stable coronary artery disease after percutaneous coronary intervention. Heart Vessels. 2023;38(10):1205–17.PubMedCrossRef

10.

Jonik S, Kageyama S, Ninomiya K, Onuma Y, Kochman J, Grabowski M, et al. Five-year outcomes in patients with multivessel coronary artery disease undergoing surgery or percutaneous intervention. Sci Rep. 2024;14(1):3218.PubMedPubMedCentralCrossRef

11.

Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524–33.PubMedCrossRef

12.

Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17(11):1410–22.PubMedCrossRef

13.

Hu B, Yang X-R, Xu Y, Sun Y-F, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–22.PubMedCrossRef

14.

Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of Systemic immune-inflammation index in cancer: a meta-analysis. J Cancer. 2018;9(18):3295–302.PubMedPubMedCentralCrossRef

15.

Zhong J-H, Huang D-H, Chen Z-Y. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(43):75381–8.PubMedPubMedCentralCrossRef

16.

Yang Y-L, Wu C-H, Hsu P-F, Chen S-C, Huang S-S, Chan WL, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest. 2020;50(5):e13230.PubMedCrossRef

17.

Geng Y, Shao Y, Zhu D, Zheng X, Zhou Q, Zhou W, et al. Systemic immune-inflammation index predicts prognosis of patients with esophageal squamous cell carcinoma: a propensity score-matched analysis. Sci Rep. 2016;6:39482.PubMedPubMedCentralCrossRef

18.

Saylik F, Akbulut T. Systemic immune-inflammation index predicts major cardiovascular adverse events in patients with ST-segment elevated myocardial infarction. Arq Bras Cardiol. 2022;119(1):14–22.PubMedPubMedCentral

19.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.PubMedPubMedCentralCrossRef

20.

Lo CK-L, Mertz D, Loeb MJBmrm. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:1–5.

21.

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.PubMedCrossRef

22.

Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JPT, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):ED000142.

23.

Patsopoulos NA, Evangelou E, Ioannidis JPA. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. 2008;37(5):1148–57.PubMedPubMedCentralCrossRef

24.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research ed). 1997;315(7109):629–34.PubMedCrossRef

25.

Gur DO, Efe MM, Alpsoy S, Akyüz A, Uslu N, Çelikkol A, et al. Systemic immune-inflammatory index as a determinant of atherosclerotic burden and high-risk patients with acute coronary syndromes. Arq Bras Cardiol. 2022;119(3):382–90.PubMedPubMedCentral

26.

Shi S, Kong S, Ni W, Lu Y, Li J, Huang Y, et al. Association of the systemic immune-inflammation index with outcomes in acute coronary syndrome patients with chronic kidney disease. J Inflamm Res. 2023;16:1343–56.PubMedPubMedCentralCrossRef

27.

Demirci G, Şahin AA, Aktemur T, Demir AR, Çetin İ, Hüseyin K, et al. Relationship between systemic immune-inflammation index and no-reflow in percutaneous coronary intervention for saphenous grafts. Biomark Med. 2023;17(8):427–35.PubMedCrossRef

28.

Öcal L, Keskin M, Cerşit S, Eren H, Özgün Çakmak E, Karagöz A, et al. Systemic immune-inflammation index predicts in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction. Coron Artery Dis. 2022;33(4):251–60.PubMedCrossRef

29.

Fan W, Zhang Y, Gao X, Liu Y, Shi F, Liu J, et al. The prognostic value of a derived neutrophil-lymphocyte ratio in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Clin Appl Thromb Hemost. 2021;27:10760296211034580.PubMedPubMedCentralCrossRef

30.

Wei X, Zhang Z, Wei J, Luo C. Association of systemic immune inflammation index and system inflammation response index with clinical risk of acute myocardial infarction. Front Cardiovasc Med. 2023;10:1248655.PubMedPubMedCentralCrossRef

31.

Bibek S-B, Xie Y, Gao J-J, Wang Z, Wang J-F, Geng D-F. Role of pre-procedural C-reactive protein level in the prediction of major adverse cardiac events in patients undergoing percutaneous coronary intervention: a meta-analysisof longitudinal studies. Inflammation. 2015;38(1):159–69.PubMedCrossRef

32.

Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–22.PubMedCrossRef

33.

Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J Cancer. 2018;9(18):3295–302.PubMedPubMedCentralCrossRef

34.

Ma J, Li K. Systemic immune-inflammation index is associated with coronary heart disease: a cross-sectional study of NHANES 2009–2018. Front Cardiovasc Med. 2023;10:1199433.PubMedPubMedCentralCrossRef

35.

Xing Q, Zhao X, Xie L, Chen X, Wang Y, Xie Y. Advances in non-pharmacological management of Parkinson's disease complicated with blood pressure abnormalities. J Physiol Pharmacol. 2023;74(4):369–75

36.

Dziedzic EA, Gąsior JS, Tuzimek A, Paleczny J, Junka A, Dąbrowski M, et al. Investigation of the associations of novel inflammatory biomarkers-Systemic Inflammatory Index (SII) and Systemic Inflammatory Response Index (SIRI)-with the severity of coronary artery disease and acute coronary syndrome occurrence. Int J Mol Sci. 2022;23(17):9553.

37.

Liu Y, Ye T, Chen L, Jin T, Sheng Y, Wu G, et al. Systemic immune-inflammation index predicts the severity of coronary stenosis in patients with coronary heart disease. Coron Artery Dis. 2021;32(8):715–20.PubMedCrossRef

38.

Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013;339(6116):161–6.PubMedPubMedCentralCrossRef

39.

Döring Y, Soehnlein O, Weber C. Neutrophil extracellular traps in atherosclerosis and atherothrombosis. Circ Res. 2017;120(4):736–43.PubMedCrossRef

40.

Li L, Ma Y, Geng X-B, Tan Z, Wang J-H, Cui C, et al. Platelet-to-lymphocyte ratio relates to poor prognosis in elderly patients with acute myocardial infarction. Aging Clin Exp Res. 2021;33(3):619–24.PubMedCrossRef

41.

Alexopoulos D, Xenogiannis I, Vlachakis P, Tantry U, Gurbel PA. Peri-procedural platelet reactivity in percutaneous coronary intervention. Thromb Haemost. 2018;118(7):1131–40.PubMedCrossRef

42.

Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA. 2011;306(11):1215–23.PubMedCrossRef

43.

Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011;124(10):1132–7.PubMedCrossRef

44.

Chen C, Cong BL, Wang M, Abdullah M, Wang XL, Zhang YH, et al. Neutrophil to lymphocyte ratio as a predictor of myocardial damage and cardiac dysfunction in acute coronary syndrome patients. Integr Med Res. 2018;7(2):192–9.PubMedPubMedCentralCrossRef

45.

Sen N, Afsar B, Ozcan F, Buyukkaya E, Isleyen A, Akcay AB, et al. The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Atherosclerosis. 2013;228(1):203–10.PubMedCrossRef

46.

Park J-S, Seo K-W, Choi B-J, Choi S-Y, Yoon M-H, Hwang G-S, et al. Importance of prognostic value of neutrophil to lymphocyte ratio in patients with ST-elevation myocardial infarction. Medicine. 2018;97(48): e13471.PubMedPubMedCentralCrossRef

47.

Tamhane UU, Aneja S, Montgomery D, Rogers E-K, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102(6):653–7.PubMedCrossRef

48.

Kurtul A, Yarlioglues M, Murat SN, Ergun G, Duran M, Kasapkara HA, et al. Usefulness of the platelet-to-lymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Am J Cardiol. 2014;114(3):342–7.PubMedCrossRef

49.

Fest J, Ruiter R, Ikram MA, Voortman T, van Eijck CHJ, Stricker BH. Reference values for white blood-cell-based inflammatory markers in the Rotterdam Study: a population-based prospective cohort study. Sci Rep. 2018;8(1):10566.PubMedPubMedCentralCrossRef

50.

Erdoğan M, Erdöl MA, Öztürk S, Durmaz T. Systemic immune-inflammation index is a novel marker to predict functionally significant coronary artery stenosis. Biomark Med. 2020;14(16):1553–61.PubMedCrossRef

51.

Candemir M, Kiziltunç E, Nurkoç S, Şahinarslan A. Relationship between Systemic Immune-Inflammation Index (SII) and the severity of stable coronary artery disease. Angiology. 2021;72(6):575–81.PubMedCrossRef

52.

Wang K-Y, Zheng Y-Y, Wu T-T, Ma Y-T, Xie X. Predictive value of Gensini score in the long-term outcomes of patients with coronary artery disease who underwent PCI. Front Cardiovasc Med. 2022;8:778615.PubMedPubMedCentralCrossRef

53.

Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. Kardiol Pol. 2014;72(12):1253–379.PubMedCrossRef

54.

Huang J, Zhang Q, Wang R, Ji H, Chen Y, Quan X, et al. Systemic immune-inflammatory index predicts clinical outcomes for elderly patients with acute myocardial infarction receiving percutaneous coronary intervention. Med Sci Monit. 2019;25:9690–701.PubMedPubMedCentralCrossRef

55.

56.

Wang J, Zhang F, Liu L, Gao M, Song X, Li Y, et al. Prognostic value of GRACE risk score combined with systemic immune-inflammation index in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention. Angiology. 2023:33197231213674. Online ahead of print.

57.

Zhu Y, Qiu H, Wang Z, Shen G, Li W. Predictive value of systemic immune-inflammatory index combined with CHA2DS2-VASC score for contrast-induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Int Urol Nephrol. 2023;55(11):2897–903.PubMedCrossRef

Title: Systemic immune-inflammation index as a novel predictor of major adverse cardiovascular events in patients undergoing percutaneous coronary intervention: a meta-analysis of cohort studies
Authors: Chunyu Zhang
Minghao Li
Lin Liu
Li Deng
Xie Yulei
Yi Zhong
Bin Liao
Lu Yu
Jian Feng
Publication date: 01-12-2024
Publisher: BioMed Central
Keyword: Acute Coronary Syndrome
Published in: BMC Cardiovascular Disorders / Issue 1/2024
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-024-03849-4

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Systemic immune-inflammation index as a novel predictor of major adverse cardiovascular events in patients undergoing percutaneous coronary intervention: a meta-analysis of cohort studies

Abstract

Background

Methods

Results

Conclusions

Trial registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2024

Contrasting the relationship of serum uric acid/albumin ratio on quantitative flow ratio with other multiple composite parameters in patients with suspected coronary artery disease

Transcatheter aortic valve implantation versus surgical aortic valve replacement for pure aortic regurgitation: a systematic review and meta-analysis of 33,484 patients

Low HDL cholesterol and the eNOS Glu298Asp polymorphism are associated with inducible myocardial ischemia in patients with suspected stable coronary artery disease

The usefulness of contrast echocardiography in the evaluation of cardiac masses: a multicenter study

Mycn ameliorates cardiac hypertrophy-induced heart failure in mice by mediating the USP2/JUP/Akt/β-catenin cascade

Coronary artery disease severity and risk stratification of patients with non ST-elevation acute coronary syndrome using CHA2DS2-VASc-HSF score

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page